- Home
- CULP vs SKYE Comparison
CULP vs SKYE Comparison
Compare CULP & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CULP
- SKYE
- Stock Information
- Founded
- CULP 1972
- SKYE 2012
- Country
- CULP United States
- SKYE United States
- Employees
- CULP N/A
- SKYE N/A
- Industry
- CULP Textiles
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- CULP Consumer Discretionary
- SKYE Health Care
- Exchange
- CULP Nasdaq
- SKYE Nasdaq
- Market Cap
- CULP 52.7M
- SKYE 46.5M
- IPO Year
- CULP N/A
- SKYE N/A
- Fundamental
- Price
- CULP $3.94
- SKYE $1.34
- Analyst Decision
- CULP
- SKYE Strong Buy
- Analyst Count
- CULP 0
- SKYE 5
- Target Price
- CULP N/A
- SKYE $14.75
- AVG Volume (30 Days)
- CULP 15.6K
- SKYE 404.7K
- Earning Date
- CULP 12-03-2025
- SKYE 11-10-2025
- Dividend Yield
- CULP N/A
- SKYE N/A
- EPS Growth
- CULP N/A
- SKYE N/A
- EPS
- CULP N/A
- SKYE N/A
- Revenue
- CULP $207,391,000.00
- SKYE N/A
- Revenue This Year
- CULP $1.93
- SKYE N/A
- Revenue Next Year
- CULP $2.77
- SKYE N/A
- P/E Ratio
- CULP N/A
- SKYE N/A
- Revenue Growth
- CULP N/A
- SKYE N/A
- 52 Week Low
- CULP $3.42
- SKYE $1.14
- 52 Week High
- CULP $5.94
- SKYE $5.75
- Technical
- Relative Strength Index (RSI)
- CULP 40.60
- SKYE 33.54
- Support Level
- CULP $3.86
- SKYE $1.40
- Resistance Level
- CULP $4.03
- SKYE $1.59
- Average True Range (ATR)
- CULP 0.11
- SKYE 0.10
- MACD
- CULP -0.01
- SKYE 0.06
- Stochastic Oscillator
- CULP 32.29
- SKYE 3.09
About CULP Culp Inc.
Culp Inc manufactures, markets mattress fabrics for bedding and upholstery fabrics for residential, commercial, and hospitality furnishings. The company has two operating segments: Mattress fabrics, which generate maximum revenue, and Upholstery fabrics. The mattress fabrics segment manufactures, sources, and sells fabrics and mattress covers to bedding manufacturers. The upholstery fabrics segment develops, sources, manufactures, and sells fabrics to residential, commercial, and hospitality furniture manufacturers. Geographically, it derives key revenue from the United States of America.
About SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.